Clinical Trials Sector Scorecard, Q2 2022 Update - Thematic Research

Clinical Trials Sector Scorecard, Q2 2022 Update - Thematic Research

Summary

The Virtual Care Landscape Saw Activity in Q2 2022: In Q2 2022, there was increased activity in the virtual care space. Compared to Q1 2022, Novo Nordisk initiated more trials with virtual components and also posted more jobs related to virtual care. Daiichi Sankyo and Takeda are planning a study in Japan that will look at the feasibility of using a wearable device to track lifestyle habits. In May, Pfizer acquired ResApp Health, a digital health company developing smartphone apps for the diagnosis and management of respiratory disease, and Roche partnered with Kaiku Health to offer cancer symptom management and support to clinics and patients via a digital platform.

Companies Were Also Active in ESG Initiatives and Continued to Partner with AI Vendors: In Q2 2022, several companies announced ESG initiatives. This included the announcement that Merck KGaA was going to invest in sites around the world with a focus on water consumption, waste management, and energy efficiency. Sanofi also announced several social initiatives, including the successful pricing of its first bond linked on improving access to essential medicine, the launch of its Diversity, Equity & Inclusion (DE&I) board, and the launch of Foundation S - The Sanofi Collective, its philanthropic endowment fund. In Q2 2022, pharma companies continued to partner with AI vendors like PathAI, VantAI, Standigm, and Owkin.

Scope

• GlobalData’s Clinical Trials Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the clinical trial sector over the next two to four years.
• These themes are Virtual Care, Rare Disease, Orphan Designated Drugs, Strategic Alliances, Real-world Evidence, AI, ESG, Cybersecurity, Cloud Computing, and Blockchain.
• The scorecard includes 53 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
• It is important to note that this scorecard is not an assessment of current performance of a company in a theme, but a view of future performance based on current levels of activity and investment.
• The methodology section contains information on what data sources were used to generate the thematic scores for each company.
• The scorecard is live on the PIC and will be updated quarterly.

• Identify the key clinical trial themes for the next 2-4 years and learn how they will impact the market.
• Understand which key themes should be addressed to drive share price.
• Understand which companies are best positioned for success within critical themes and why.
• Learn which companies have underinvested in key themes and are most vulnerable to disruption.
• Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
• Help identify future winners and losers in drug development to inform partnership strategies.